Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Méry-Mignard D, Ouldkaci M, Besmaine A, Dupont-André G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E. Wasserman E, et al. Among authors: mahjoubi m. J Clin Oncol. 1999 Jun;17(6):1751-9. doi: 10.1200/JCO.1999.17.6.1751. J Clin Oncol. 1999. PMID: 10561212 Clinical Trial.
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, Mahjoubi M, Méry-Mignard D, Rougier P. Ducreux M, et al. Among authors: mahjoubi m. J Clin Oncol. 1999 Sep;17(9):2901-8. doi: 10.1200/JCO.1999.17.9.2901. J Clin Oncol. 1999. PMID: 10561369
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Guastalla J, Viens P, Faivre S, Chahine A, Spielman M, Bensmaïne A, Marty M, Mahjoubi M, Cvitkovic E. Alexandre J, et al. Among authors: mahjoubi m. J Clin Oncol. 2000 Feb;18(3):562-73. doi: 10.1200/JCO.2000.18.3.562. J Clin Oncol. 2000. PMID: 10653871 Clinical Trial.
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M. Rougier P, et al. Among authors: mahjoubi m. J Clin Oncol. 1997 Jan;15(1):251-60. doi: 10.1200/JCO.1997.15.1.251. J Clin Oncol. 1997. PMID: 8996150 Clinical Trial.
Circadian rhythm of irinotecan tolerability in mice.
Filipski E, Lemaigre G, Liu XH, Méry-Mignard D, Mahjoubi M, Lévi F. Filipski E, et al. Among authors: mahjoubi m. Chronobiol Int. 2004 Jul;21(4-5):613-30. doi: 10.1081/cbi-120040183. Chronobiol Int. 2004. PMID: 15470958
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.
Bonneterre J, Spielman M, Guastalla JP, Marty M, Viens P, Chollet P, Roché H, Fumoleau P, Mauriac L, Bourgeois H, Namer M, Bergerat JP, Misset JL, Trandafir L, Mahjoubi M. Bonneterre J, et al. Among authors: mahjoubi m. Eur J Cancer. 1999 Oct;35(10):1431-9. doi: 10.1016/s0959-8049(99)00174-4. Eur J Cancer. 1999. PMID: 10673974
65 results